



**Current Research Studies Open for
Patient Enrollment at Sacred Heart Cancer Center**

For more information about these clinical trials or to see if you may qualify for enrollment, please contact one of our Clinical Research Coordinators: Betsy Brou, RN (850-416-4611), Toni Hyatt, RN (850-416-2730) or Walid Kara (850-416-6316).

Cancer Type Trial # Trial Information/Description

Brain		
	A221101	The Use of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma : A Randomized, Novel Adaptive Design Study.
Breast		
	SWOG 1207	Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer
	SWOG S1418	A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
NHL		
	NHL-008	Randomized study of lenalidomide plus rituximab maintenance therapy followed by lenalidomide single-agent maintenance versus rituximab maintenance in subjects with relapsed/refractory follicular, marginal zone or mantle cell lymphoma .
Gastrointestinal (GI)		
	BMS CA209-577	A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal, or Gastroesophageal Junction Cancer
Endometrial		
	NRG-GY001	A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus



**Current Research Studies Open for
Patient Enrollment at Sacred Heart Cancer Center**

Lung		
	BMS CA209-384	A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer Who Received 4 Months of Nivolumab at 3mg/kg
	S1403	A Randomized Trial of Afatinib + Cetuximab VS Afatinib Alone in Treatment-Naïve Patients with Advanced, EGFR Mutated NSCLC
Multiple Myeloma		
	E1A11	Randomized Trial of Bortezomib + Lenalidomide + Dexamethasone (VRd) vs. Carfilzomib + Lenalidomide + Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed, Symptomatic Multiple Myeloma.
Supportive		
	CONNECT MDS/AML	The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
	informCLL	A Disease Registry for Patients with Chronic Lymphocytic Leukemia